UPCOMING MILESTONES
Phase 2a topline data – Q1 2024
Redx is a clinical-stage biotechnology company focused on the discovery and development of novel, small molecule, targeted medicines for the treatment of fibrotic disease, cancer and the emerging area of cancer-associated fibrosis
Our core strengths in medicinal chemistry and translational science enable us to discover and develop potentially differentiated, novel compounds against biologically or clinically validated targets where there is the opportunity to create best-in-class or first-in-class treatments for diseases of unmet medical need. We have built an attractive portfolio of assets and have a strong track record of drug discovery having delivered five molecules to clinical stage development. Our focus is on advancing our differentiated ROCK portfolio which includes our lead asset, RXC007, a next-generation, selective ROCK2 inhibitor for the treatment of interstitial lung diseases and RXC008, a potential first-in-class GI-targeted ROCK inhibitor for the treatment of fibrostenotic Crohn's disease. Our oncology pipeline is led by RXC004, a Porcupine inhibitor targeting Wnt-ligand dependent tumours, in combination with anti-PD-1 therapy; and our world-class drug discovery engine is advancing a pipeline of research programmes and collaborations in both fibrotic diseases and oncology.
Lead: Idiopathic pulmonary fibrosis (IPF)
Potential: ILD, cancer-associated fibrosis
Phase 2a topline data – Q1 2024
Biliary tract cancer and pancreatic cancer
Fibrosis, cancer-associated fibrosis
Progress programmes – target of 2 IND’s by 2025
Research Targets
(Multiple Programmes)
Oncology & fibrosis
MAPK Pathway Target
Oncology
Progress Jazz Collaboration
DDR: Discoidin Domain Receptor; RAF: Rapidly accelerated fibrosarcoma; GI: Gastrointestinal; MAPK: Mitogen-activated protein kinase; MSS mCRC: Microsatellite-Stable Metastatic Colorectal Cancer; ROCK: Rho associated protein kinase
UPCOMING MILESTONES
Phase 2a topline data – Q1 2024
UPCOMING MILESTONES
CTA submission – end 2023
UPCOMING MILESTONES
Topline data in combination with anti-PD-1 – H2 2023
UPCOMING MILESTONES
Progress programmes – target of 2 IND’s by 2025
Research Targets
(Multiple Programmes)
UPCOMING MILESTONES
Licensed to AstraZeneca
UPCOMING MILESTONES
Sold to Jazz Pharmaceuticals
MAPK Pathway Target
UPCOMING MILESTONES
Progress Jazz Collaboration
DDR: Discoidin Domain Receptor; RAF: Rapidly accelerated fibrosarcoma; GI: Gastrointestinal; MAPK: Mitogen-activated protein kinase; MSS mCRC: Microsatellite-Stable Metastatic Colorectal Cancer; ROCK: Rho associated protein kinase
31-May-2023
Redx to Present at Jefferies Global Healthcare Conference in New York
17-May-2023
Interim Results for the Six Months Ended 31 March 2023
12-May-2023
Discovery of Pirtobrutinib Recognised with Plaque
11-May-2023
Redx Presents Preclinical Efficacy Data for RXC007 Showing Significant Results in Cancer-Associated Fibrosis Models
At Redx, our ambition is to create world leading medicines that will transform patients’ lives, by delivering better medicines faster.
Our core strengths in medicinal chemistry and translational science enable us to discover and develop potentially differentiated, novel compounds against biologically or clinically validated targets where there is the opportunity to create best-in-class or first-in-class treatments for diseases of unmet medical need.
Our five core company values that underpin everything we do:
We stand or fall by quality data
The market waits for no-one
Bright ideas fuel our pipeline
We can’t win by giving up
Together we are stronger